Oryzon Genomics

Spanish biotech Oryzon Genomics is focused on epigenetics. Iadademstat is being explored for acute leukaemias, small-cell lung cancer (SCLC) and neuroendocrine tumours. Central nervous system (CNS) asset vafidemstat has completed several Phase IIa trials and a Phase IIb trial in borderline personality disorder, and is in a Phase IIb trial for schizophrenia.

Equities

Equities by Sector

Sectors

Thematics

Latest

Inside the mind of investors: Oberon Investments

UK equities: Not wrong to call them, but Europe surprised

MediaWatch – What now?

Audiovisual

Latest

Take on Trusts – March 2025

Patria Private Equity Trust in 60 seconds

OSE Immunotherapeutics — Lusvertikimab and the future of IBD: KOL insights post-ECCO webinar

About Edison

About Edison

Careers

Oryzon Genomics (BME: ORY)

Latest Insights

Oryzon (BME: ORY) publishes results of vafidemstat in PMS

Oryzon Genomics — All steady heading into 2025

Oryzon (BME: ORY) publishes REIMAGINE results in prestigious journal

Oryzon Genomics (BME: ORY) doses first patient in new MDS trial

Sector

Equity Analyst

Key Management

Oryzon Genomics — Doubling down on clinical activity in 2024

Oryzon Genomics — FDA green light for SCLC combination trial

Oryzon Genomics — Third time is a charm; INNOVATIVE SME Seal

Oryzon Genomics — Approaching a period of inflection

Oryzon Genomics — KOL event: Offering a real-world solution in BPD

Oryzon Genomics — PORTICO update with planned FDA EoP2

Executive interview with Carlos Buesa, CEO of Oryzon Genomics

Oryzon Genomics — Grant to bolster ALS pipeline, add funding

Oryzon Genomics — Key €45m funding to back strategic priorities

Oryzon Genomics — Q323 recap ahead of key clinical stages

Oryzon Genomics — Favorable safety reported in PORTICO Phase II

Oryzon Genomics — Grants provide confidence and expand portfolio

Oryzon Genomics — H123 progress and results came in as expected

Oryzon Genomics — Positive safety data for vafidemstat in PORTICO

Oryzon Genomics — Advancing on multiple clinical fronts in Q1

Oryzon Genomics — Promising PORTICO interim results

Oryzon Genomics — Clinical milestone reached with FRIDA initiation

Oryzon Genomics — New clinical candidate expands CNS portfolio

Oryzon Genomics — Catalysts on the horizon in FY23

Oryzon Genomics — KOL event puts near-term catalysts in the spotlight

Oryzon Genomics — Progress in oncology and CNS in FY22

Oryzon Genomics — First Phase II patient enrolled is clinical milestone

Oryzon Genomics — Lead asset granted expansion into combo therapies

Oryzon Genomics — Positive ALICE readouts pave way in AML

Oryzon Genomics — IND granted for collaborative Phase II trial

Oryzon Genomics — Clinical ramp in Q3; several catalysts approaching

Oryzon Genomics — Encouraging safety data in PORTICO

Oryzon Genomics — Preclinical collaboration in orphan disease

Oryzon Genomics — Costs up but company remains well funded

Oryzon Genomics — CRADA win to provide a halo effect

Oryzon Genomics — Key milestones and extended cash runway

Oryzon Genomics — Continued positive responses in ALICE trial

Oryzon Genomics — FRIDA funding and orphan drug designation

Oryzon Genomics — Planning iadademstat’s path to market

Oryzon Genomics — Large response benefit consistent in ALICE trial

Oryzon– Edison Open House interview

Oryzon Genomics — Response rates consistently high in ALICE trial

Oryzon Genomics — Final update from Phase IIa CLEPSIDRA trial

Oryzon Genomics — Third positive update from Phase II ALICE trial

Oryzon Genomics — More data support vafidemstat for aggression

Oryzon Genomics — More to come after a year of data readouts

Oryzon Genomics — Maturing ALICE trial dataset continues to impress

Oryzon Genomics — Interim Phase II CLEPSIDRA results at ESMO

Oryzon Genomics — Interim data from Phase IIa ETHERAL AD study

Oryzon Genomics — Positive signals from first ALICE trial dataset

Oryzon Genomics — First vafidemstat efficacy data

Oryzon Genomics — A year of data readouts

Executive interview – Oryzon

Oryzon Genomics — Ramping up R&D activity; catalysts in 2019

Oryzon Genomics — Awaiting for eventful 2019

Oryzon Genomics — Phase IIa trial in Alzheimer’s disease initiated

Oryzon Genomics — Multiple data readouts in 2019 within cash reach

Oryzon Genomics — New data support holistic effects of ORY-2001

Oryzon Genomics — ORY-2001 and ORY-3001 next in focus

Oryzon Genomics — Maturing epigenetics portfolio